Case studyFortune 100: 80% less compliance workRead the Story
RiskWatch
Updated May 15, 2026 · 10 platforms evaluated

Top 10 Compliance Management Software for Pharmaceuticals in 2026: A Buyer-First Comparison

Honest 2026 ranking of the 10 best pharmaceutical compliance platforms for 21 CFR Part 11, GxP, GAMP 5, ICH Q10, EMA Annex 11, and DSCSA readiness.

By RiskWatch Editorial · Pharmaceutical Risk and Compliance Software Research

Verdict

TL;DR

If you run quality at a pharmaceutical manufacturer, contract development organisation, or specialty biotech in 2026 and you want one platform that covers 21 CFR Part 11 electronic records and signatures, the full GxP envelope (GMP / GLP / GCP / GDP / GVP), ICH Q10 pharmaceutical quality system, ISPE GAMP 5 validated systems, EMA Annex 11, and DSCSA trading-partner readiness, the shortlist narrows quickly. RiskWatch ranks first on our weighted score because its 40+ framework library carries pre-mapped 21 CFR Part 11 + GAMP 5 + ICH Q10 + Annex 11 + Annex 15 + DSCSA controls in one tenant with single-tenant deployment for validated environments. MasterControl is the default for a regulated commercial pharma manufacturer that wants the FDA's own document-control reference customer; Veeva Vault QMS is the natural pick for any organisation already running Vault Clinical, RIM, or Safety; ETQ Reliance and Sparta TrackWise Digital fit large biopharma running deep CAPA, change control, and supplier quality on a validated enterprise QMS; ComplianceQuest is the Salesforce-native option; Greenlight Guru fits combination products with a primary medical-device DNA; Qualio fits emerging biotech under series C; Pilgrim is the IQVIA-aligned mid-market pick; Optro (formerly AuditBoard) carries the public-pharma SOX 404 + IT general controls workload that QMS tools do not. Pick by where your validated environment lives and whether the platform will survive an FDA Form 483, EMA inspection, or MHRA data-integrity audit, not by analyst-quadrant placement.

Pick by use case

Where each platform fits

Multi-framework pharma manufacturer running 21 CFR Part 11 + GAMP 5 + ICH Q10 + Annex 11 + DSCSA
RiskWatch: 40+ framework libraries with pre-mapped 21 CFR Part 11 electronic records and signatures + GAMP 5 categories + ICH Q10 + Annex 11 + Annex 15 + DSCSA controls; single-tenant deployment for validated environments.
Commercial-stage manufacturer that wants the FDA's reference document-control tool
MasterControl: Used by the US FDA itself for internal quality processes; deepest installed base in regulated pharma manufacturing for 21 CFR Part 11 document control, training, and CAPA.
Pharma already running Veeva Vault Clinical, RIM, Safety, or Quality Docs
Veeva Vault QMS: Native interoperability with the Vault Clinical Operations, RIM, and Safety suites used by 18 of the top 20 global pharma; one tenant for QMS, document control, and regulatory submission.
Large biopharma running deep CAPA, supplier quality, and change control on a validated enterprise QMS
ETQ Reliance: Hexagon-owned since January 2022; deepest configurable CAPA, change control, supplier quality, and document-control workflow for enterprise pharma; 40+ pre-built compliance applications.
Top-20 global pharma running validated QMS at site + global rollout scale
Sparta TrackWise Digital: Honeywell Forge-owned since 2021; TrackWise is the historical incumbent at 9 of the top 10 global pharma; TrackWise Digital is the AWS-hosted cloud successor with native validation.
Salesforce-anchored pharma running combined supplier + clinical + commercial quality
ComplianceQuest: Salesforce-native EQMS + EHS + PLM with 100% cloud architecture; multi-tenant SaaS with validated configuration; deepest Salesforce AppExchange depth in pharma quality.
Pharma combination products and biotech with a medical-device-first DNA
Greenlight Guru: Purpose-built for MedTech + combination products (21 CFR Part 820 + ISO 13485 + EU MDR + IVDR); strongest fit when the drug-device combination dominates the quality brief over pure GMP.
Emerging biotech, generics, or specialty pharma under series C
Qualio: Cloud-native EQMS published at $24K-$50K entry; targeted at virtual pharma, generics, and CDMO clients under 250 staff; fastest first-Phase-1-submission readiness for emerging biotech.
Mid-market pharma needing IQVIA-aligned validated QMS with SmartSolve heritage
Pilgrim Quality Solutions: IQVIA-owned since 2015; SmartSolve EQMS plus iComplyGRC for compliance and supplier risk; deep pharma + medical-device + life-sciences pedigree across 800+ customers.
Public-company pharma owning SOX 404 + IT GCs + GxP IT in one tenant
Optro (formerly AuditBoard): Deepest internal-audit and SOX 404 platform in the category with 1,585+ G2 reviews at 4.6/5; pharma IT teams use it for SOX, IT general controls, and CSA-aligned IT-risk testing alongside a QMS.

Pharmaceutical compliance management is not one buying category. A virtual specialty pharma running its first Phase 1 trial needs a cloud QMS that can stand up validated SOP control and 21 CFR Part 11 electronic signatures inside 60 days for under $50K. A top-20 global manufacturer needs a validated enterprise platform that handles CAPA, deviation, change control, supplier quality, training, and document control across 30+ sites with site-by-site validation packages and an FDA-grade audit trail. A combination-product MedTech needs a system that handles 21 CFR Part 820 design controls alongside 21 CFR Part 211 GMP and 21 CFR Part 11 electronic records, in one tenant. A contract development and manufacturing organisation needs to run all of the above on behalf of multiple clients with cross-client isolation. The ten platforms in this ranking each solve part of that brief; none solves all of it equally well.

We considered 22 platforms across G2's Quality Management QMS and Life Sciences Compliance categories, the Capterra Pharmaceutical Software shortlist, Gartner's QMS Hype Cycle, and ISPE vendor catalogues. We cut to ten by removing pure document-management tools without an embedded quality engine (Box, M-Files in their non-life-sciences shape), excluding ERP-led quality modules whose validated lifecycle is sold as a customisation (SAP QM, Oracle Agile PLM Quality), and dropping pure trust-management platforms that do not address GxP or DSCSA (Vanta, Drata, Secureframe in their generic SOC 2 shape). The result is ten platforms a pharma quality, regulatory, or IT compliance leader might actually shortlist in 2026.

Pricing transparency in pharma compliance is worse than in adjacent categories. Eight of the ten platforms here will not publish a list price, and the two that do (Qualio and Greenlight Guru) publish only entry-tier ranges. That is a category problem driven by site-by-site validation variance, not a competitive moat. We have triangulated prices for the opaque vendors from two or more independent third-party sources (Vendr, SecureLeap, SoftwareAdvice, SelectHub) and dated each estimate. Pharma-specific evaluation criteria layered on top of the default methodology: 21 CFR Part 11 electronic records and signatures coverage, GAMP 5 Category 3 / 4 / 5 software classification fit, validated supplier audit history, FDA Form 483 inspection survivability, EMA Annex 11 + Annex 15 alignment, MHRA data-integrity ALCOA+ coverage, ICH Q10 pharmaceutical quality system mapping, DSCSA trading-partner messaging, and Computer Software Assurance (CSA) readiness for the post-September 2022 risk-based testing approach.

At-a-glance

Comparison table

The 10 platforms scored on the methodology weights at the bottom of this page. Pricing-transparency pill is the buyer-honesty signal.

RankProductBest forPricing transparencyG2Verdict
1RiskWatch
RiskWatch International
Mid-market and large pharma buyers running 3+ frameworks (21 CFR Part 11 + GAMP 5 + ICH Q10 + Annex 11 + DSCSA + IT compliance such as SOX or SOC 2) who want one tenant for compliance, supplier risk, trading-partner attestation, and IT security assessment with customer-owned data residency.Partial4.5/5
60+ reviews
Pre-built 21 CFR Part 11 control library mapped to § 11.10 (controls for closed...
2MasterControl
MasterControl, Inc.
Commercial-stage pharmaceutical manufacturers, contract manufacturers, and biotechs in scale-up that want a single validated EQMS owning document control, training, CAPA, change control, batch records, and supplier quality end-to-end with FDA-grade audit-trail credibility.Opaque4.3/5
540+ reviews
US Food and Drug Administration uses MasterControl for internal document and quality...
3Veeva Vault QMS
Veeva Systems Inc.
Pharma and biotech organisations already running two or more Veeva Vault applications (Clinical, RIM, Submissions, Safety) that want a QMS sharing the same validated data model and three-release-per-year cadence.Opaque4.2/5
180+ reviews
Native interoperability with Vault Clinical Operations, Vault RIM, Vault Submissions,...
4ETQ Reliance
ETQ (Hexagon AB subsidiary)
Large and global pharma running site-by-site validated rollouts who need a configurable enterprise QMS, deep supplier quality across many manufacturing sites, and an integration story with Hexagon Manufacturing Intelligence or Smart Manufacturing.Opaque4.4/5
220+ reviews
Gartner Magic Quadrant QMS Leader (2024 placement); strong analyst credibility for...
5Sparta TrackWise Digital
Sparta Systems (Honeywell company)
Top-20 global pharma, large biotech, and contract manufacturers running cloud-first quality strategies, especially those migrating from legacy on-prem TrackWise or already running Honeywell Forge / Experion across manufacturing sites.Opaque4.2/5
110+ reviews
Legacy TrackWise is installed at 9 of the top 10 global pharmaceutical companies per...
6ComplianceQuest
ComplianceQuest, Inc.
Mid-market and growing pharma, biotech, and MedTech customers already running Salesforce Sales Cloud, Service Cloud, or Marketing Cloud who want a cloud-native EQMS that shares the same data platform.Opaque4.7/5
280+ reviews
Salesforce-native architecture means inherited Salesforce SSO, mobile, AppExchange,...
7Greenlight Guru
Greenlight Guru, Inc.
Combination-product organisations (21 CFR Part 4 drug-device), MedTech with biologics pipelines, and biotechs whose pipeline includes device-delivered therapeutics who want one eQMS for design controls plus drug GxP.Partial4.6/5
1050+ reviews
Purpose-built for 21 CFR Part 820 design controls and ISO 13485; strongest fit for...
8Qualio
Qualio, Inc.
Emerging biotech, virtual pharma, generics, specialty pharma, and CDMOs under 250 staff that need a validated cloud EQMS stood up in 60-90 days for under $50K to support a first IND or Phase 1 trial.Partial4.6/5
380+ reviews
Published $24K-$50K entry pricing; the most transparent in this ranking outside...
9Pilgrim Quality Solutions
IQVIA (Pilgrim is an IQVIA company)
Mid-market pharma, biotech, and MedTech customers already running IQVIA clinical, commercial, or technology services who want a validated EQMS sharing the IQVIA data fabric.Opaque4.2/5
130+ reviews
IQVIA ownership since 2015; natural alignment with IQVIA clinical, commercial, and...
10Optro (formerly AuditBoard)
Optro, Inc.
Public-company pharma, large biotech, and contract manufacturers where internal audit owns SOX 404, IT general controls, and CSA-aligned IT risk testing of validated systems alongside (not instead of) a QMS.Opaque4.6/5
1820+ reviews
1,585+ G2 reviews at 4.6/5 (May 2026), the highest review volume across all GRC platforms
Calculator

Estimate the licence cost

Drag the slider to your headcount. Estimates use each vendor's published or triangulated tiers. Opaque vendors show Contact sales.

500
11.3k2.5k3.8k5k
RiskWatch
Professional (≤ 1,000 employees)
$36,000/yr
MasterControl
Mid-market (est.) (quote-only tier)
Contact sales
Veeva Vault QMS
Clinical-stage (est.) (quote-only tier)
Contact sales
ETQ Reliance
Mid-market (est.) (quote-only tier)
Contact sales
Sparta TrackWise Digital
Mid-market (est.) (quote-only tier)
Contact sales
ComplianceQuest
Mid-market (est.) (quote-only tier)
Contact sales
Greenlight Guru
Enterprise (est.) (quote-only tier)
Contact sales
Qualio
Premium (quote-only tier)
Contact sales
Pilgrim Quality Solutions
Mid-market (est.) (quote-only tier)
Contact sales
Optro (formerly AuditBoard)
Starter (est.) (quote-only tier)
Contact sales

Estimates only. Opaque-pricing vendors do not publish list prices; bands are triangulated from public third-party sources dated 2026-05-15. Implementation services, module add-ons, and renewal escalators are extra.

Pick your own weights

Decision matrix

Default weights match the methodology at the bottom of this page. Drag the sliders to match your priorities and re-rank in real time.

20%

How quickly a non-technical control owner reaches first value

20%

Module coverage across ERM, IT, audit, TPRM, BC

20%

Price to value ratio at mid-market

15%

Quality and responsiveness of vendor support

15%

Handling 5,000+ employees, multiple entities, regions

10%

Breadth of native connectors and APIs

Weights sum: 100%
  1. 1
    RiskWatch
    Editorial rank #1
    8.64
  2. 2
    ComplianceQuest
    Editorial rank #6
    8.58
  3. 3
    MasterControl
    Editorial rank #2
    8.48
  4. 4
    Optro (formerly AuditBoard)
    Editorial rank #10
    8.37
  5. 5
    Veeva Vault QMS
    Editorial rank #3
    8.35
  6. 6
    Greenlight Guru
    Editorial rank #7
    8.32
  7. 7
    ETQ Reliance
    Editorial rank #4
    8.29
  8. 8
    Qualio
    Editorial rank #8
    8.23
  9. 9
    Sparta TrackWise Digital
    Editorial rank #5
    8.19
  10. 10
    Pilgrim Quality Solutions
    Editorial rank #9
    8.08
Switching cost

Migration matrix

Read row-to-column. Row = today's platform, column = tomorrow's. Colour reflects realistic switching effort, not vendor sales pitches.

From / To
RiskWatch
MasterControl
Veeva Vault QMS
ETQ Reliance
Sparta TrackWise Digital
ComplianceQuest
Greenlight Guru
Qualio
Pilgrim Quality Solutions
Optro
RiskWatch.MEMMEEEME
MasterControlE.EEEEEEEE
Veeva Vault QMSEE.EMEEEEE
ETQ RelianceEEE.EEEEEE
Sparta TrackWise DigitalEEEE.EEEEE
ComplianceQuestEMMMH.EEME
Greenlight GuruMMMHHE.EME
QualioMHMHHME.HM
Pilgrim Quality SolutionsEMEMMEEE.E
OptroEMEMMEEEM.
Easy (E)Moderate (M)Hard (H)Source: per-vendor migration field with radar-profile fallback. Treat as a directional guide, not a quote.
Methodology

How we scored and why you should trust it

The methodology is the only thing keeping this page honest. Read it carefully and apply your own weights in the decision matrix above.

We scored each of the ten platforms on six axes: Ease of Use (20%), Feature Breadth (20%), Value (20%), Customer Support (15%), Scalability (15%), and Integrations (10%). Scores are 0-10 and calibrated within this pharmaceutical-specific category (highest features 9.5, lowest 6.5). Ratings reference G2 and Capterra figures pulled 2026-05-14. Pricing reflects the most-recent published or triangulated figures, also pulled 2026-05-14; where pricing is opaque we report a range based on two or more public third-party sources. Pharma-specific evaluation criteria layered on top: 21 CFR Part 11 § 11.10 + § 11.30 + § 11.50 + § 11.70 + § 11.100 + § 11.200 + § 11.300 coverage; GAMP 5 second-edition (July 2022) software category fit (Category 3 non-configured, Category 4 configured, Category 5 custom); ICH Q10 pharmaceutical quality system mapping; ISPE GAMP 5 validated configuration approach; EMA Annex 11 + Annex 15 alignment; MHRA Data Integrity ALCOA+; FDA Computer Software Assurance (CSA) draft guidance (September 2022) for risk-based testing; DSCSA trading-partner readiness post the Nov 27 2024 Stabilization Period and the May 27 2025 Exemptions Year; FDA Form 483 inspection survivability based on public 483 enforcement history. We re-verify this page quarterly.

Weights used in the editorial ranking

Ease of use
20%
Feature breadth
20%
Value
20%
Customer support
15%
Scalability
15%
Integrations
10%
#1

RiskWatch

RiskWatch International · Founded 1993 · Annapolis, MD, USA

Multi-framework pharma compliance platform with 21 CFR Part 11, GAMP 5, ICH Q10, Annex 11, and DSCSA in one tenant.

Partial pricingG2 4.5 · Capterra 4.6 · 60+ reviews

Summary

RiskWatch ships a pharma compliance assessment platform built around pre-mapped control libraries for 21 CFR Part 11 electronic records and signatures, ICH Q10 pharmaceutical quality system, ISPE GAMP 5 (second edition), EMA Annex 11 + Annex 15, MHRA Data Integrity ALCOA+, DSCSA, and 35+ additional frameworks including ISO 27001, SOC 2, NIST 800-53, and HIPAA. The platform runs on a survey-based assessment engine, an evidence vault with versioning, a supplier and trading-partner risk module, and a cross-mapping engine that auto-detects shared controls across 21 CFR Part 11, Annex 11, and ICH Q10. Customers include US federal healthcare programmes, regional health systems, and life-sciences customers running combined IT + quality compliance briefs. Single-tenant deployment lets pharma legal and IT keep customer-owned data residency for validated environments.

Strengths
  • Pre-built 21 CFR Part 11 control library mapped to § 11.10 (controls for closed systems) through § 11.300 (controls for identification codes / passwords) out of the box
  • ISPE GAMP 5 second-edition (July 2022) category mapping plus ICH Q10 pharmaceutical quality system library in the same tenant
  • 33-year operating history with regulated US federal customers (VA, Medicaid agencies) and life-sciences buyers running combined IT + quality compliance briefs
  • Single-tenant deployment with customer-owned data residency for validated environments; useful when QA and IT will not approve multi-tenant SaaS for GxP records
  • Supplier and trading-partner risk module supports DSCSA trading-partner attestation and the EMA Annex 11 + ICH Q9 supplier-quality angle in one workspace
  • Survey-based assessment engine works for non-technical QA owners (validation leads, document-control specialists) without SQL or workflow-builder skills
  • Evidence vault with audit-trail and ALCOA+ alignment for MHRA Data Integrity inspection prep
Weaknesses
  • Not a validated electronic QMS in the MasterControl, Veeva Vault, or TrackWise Digital sense; does not ship native CAPA, deviation, change-control, or batch-record modules out of the box
  • Public pricing remains partially opaque; we publish typical contract bands but the public site still routes buyers through a quote workflow
  • Brand awareness on G2 / Capterra in pharma quality specifically is lower than MasterControl or Veeva Vault; total third-party review volume sits below 100
  • No native validation lifecycle service (URS, FS, DS, IQ, OQ, PQ) the way MasterControl Validation Excellence Tool or Sparta TrackWise Digital ship out of the box; configuration of validated environments requires partner support
  • Audit trail meets 21 CFR Part 11 § 11.10(e) but is less granular than purpose-built pharma EQMS audit trails on field-by-field timestamping
  • UI shows operational-heritage in places; newer entrants (ComplianceQuest, Qualio) have a more polished first-run experience for SaaS-style biotech buyers
Best for

Mid-market and large pharma buyers running 3+ frameworks (21 CFR Part 11 + GAMP 5 + ICH Q10 + Annex 11 + DSCSA + IT compliance such as SOX or SOC 2) who want one tenant for compliance, supplier risk, trading-partner attestation, and IT security assessment with customer-owned data residency.

Worst for

Commercial-stage manufacturers shopping for a single validated EQMS to own CAPA, deviation, change control, training, and batch records end-to-end; MasterControl, Veeva Vault QMS, or TrackWise Digital fit that brief better.

Key features

  • Pre-built 21 CFR Part 11 library (§ 11.10 / § 11.30 / § 11.50 / § 11.70 / § 11.100 / § 11.200 / § 11.300)
  • ISPE GAMP 5 second-edition (July 2022) category mapping (Category 3 / 4 / 5)
  • ICH Q10 pharmaceutical quality system control library
  • EMA Annex 11 + Annex 15 alignment with cross-mapping to 21 CFR Part 11
  • MHRA Data Integrity ALCOA+ workflow
  • DSCSA trading-partner attestation and supplier-risk register
  • Survey-based assessment engine for QA and validation owners
  • Evidence vault with versioning and FDA-inspection-ready export

Integrations

25+ native. Notable: Microsoft Entra ID (SAML SSO), Okta, Microsoft 365 / SharePoint, Slack, Jira, Salesforce, Custom REST API.

Target size

100 to 25,000 employees · US · Canada · EU · UK · AU

#2

MasterControl

MasterControl, Inc. · Founded 1993 · Salt Lake City, UT, USA

Validated EQMS used by the US FDA itself for document control, CAPA, training, and 21 CFR Part 11 records.

Opaque pricingG2 4.3 · Capterra 4.5 · 540+ reviews

Summary

MasterControl was founded in 1993 in Salt Lake City and built the regulated-life-sciences EQMS category. The Quality Excellence suite covers document control, training management, CAPA, change control, audit, supplier quality, and risk in one validated platform. The most-cited reference customer is the US Food and Drug Administration itself, which has used MasterControl for internal quality processes since 2009. MasterControl Manufacturing Excellence added an electronic batch record (EBR) and Manufacturing Execution System (MxP) to the same tenant in 2023-2024. Sumeru Equity Partners took a majority stake in 2020; the platform serves 1,000+ regulated-industry customers across pharma, biotech, MedTech, and food and beverage.

Strengths
  • US Food and Drug Administration uses MasterControl for internal document and quality processes; the strongest reference customer in regulated life sciences
  • Deepest installed base in pharma manufacturing for 21 CFR Part 11 electronic records, electronic signatures, training, and CAPA
  • Manufacturing Excellence module added electronic batch records (EBR) and MES capabilities in 2023-2024, extending coverage from quality into shop-floor execution
  • Validation Excellence Tool (VxT) ships pre-built validation packages (IQ / OQ / PQ) that cut typical pharma validation cycles 30-50% per vendor benchmarks
  • 33-year operating history with regulated customers; consistent presence in Gartner Hype Cycle for life-sciences QMS and ISPE references
  • Strong audit-trail granularity at field-level for 21 CFR Part 11 § 11.10(e); reviewers consistently flag this for FDA Form 483 survivability
Weaknesses
  • Pricing is opaque and enterprise-tier; SoftwareAdvice and SelectHub triangulate $30K-$100K+ entry for mid-market and $200K+ for top-20 pharma
  • Sumeru Equity Partners majority ownership since 2020 raises typical PE-owned renewal-uplift risk; ask for the cap in writing
  • G2 review patterns flag legacy UI elements that newer cloud entrants (Qualio, ComplianceQuest) have moved past; mobile experience trails the SaaS-trust generation
  • Implementation is consultant-heavy; pharma deployments routinely require 6-12 months and 20-30% of first-year licence in services
  • Modern AI features (intelligent CAPA root-cause, automated SOP drafting) are behind the 2024-2026 product roadmap rather than fully shipped
  • Module-by-module pricing means Quality + Manufacturing + Validation Excellence can stack quickly toward $500K/yr for a top-20 pharma deployment
Best for

Commercial-stage pharmaceutical manufacturers, contract manufacturers, and biotechs in scale-up that want a single validated EQMS owning document control, training, CAPA, change control, batch records, and supplier quality end-to-end with FDA-grade audit-trail credibility.

Worst for

Pre-Phase-1 virtual biotech that needs a cloud QMS in 60 days for under $50K; MasterControl is over-built and over-priced for that brief, where Qualio or Greenlight Guru fit better.

Key features

  • Document control with 21 CFR Part 11 electronic signatures
  • Training management with role-based curricula and read-and-understand tracking
  • CAPA workflow with root-cause analysis and effectiveness checks
  • Change control with cross-functional approval routing
  • Supplier quality management with audit tracking
  • Audit management for internal, supplier, and regulatory inspections
  • Validation Excellence Tool (VxT) with pre-built IQ / OQ / PQ packages
  • Manufacturing Excellence with electronic batch records (EBR)

Integrations

60+ native. Notable: SAP S/4HANA, Oracle E-Business Suite, Microsoft Entra ID, Okta, Salesforce, Veeva Vault (limited), Native REST API.

Target size

100 to 1,00,000 employees · US · Canada · EU · UK · AU · APAC · LATAM

#3

Veeva Vault QMS

Veeva Systems Inc. · Founded 2007 · Pleasanton, CA, USA

Cloud QMS that snaps into the Veeva Vault Clinical, RIM, and Safety suites used by 18 of the top 20 global pharma.

Opaque pricingG2 4.2 · Capterra 4.3 · 180+ reviews

Summary

Veeva Systems was founded in 2007 by Peter Gassner and built the life-sciences cloud category around the Vault content platform. Vault QMS shipped in 2017 and shares the same data model and validated infrastructure as Vault Clinical Operations, Vault RIM, Vault Submissions, and Vault Safety. Veeva reports 18 of the top 20 global pharmaceutical companies use multiple Vault applications, which means Vault QMS is the natural pick when the customer already runs Vault clinical or regulatory. The platform is multi-tenant SaaS with validated configuration delivered on the Veeva release cadence (three releases per year). Vault QMS coverage spans deviations, CAPA, change control, complaints, supplier quality, audit, and quality issue management.

Strengths
  • Native interoperability with Vault Clinical Operations, Vault RIM, Vault Submissions, and Vault Safety on the same data model and validated infrastructure
  • Veeva reports 18 of the top 20 global pharmaceutical companies use multiple Vault applications; deepest top-20-pharma installed base
  • Three-release-per-year cadence with validation packages delivered by Veeva; reduces customer validation burden vs single-tenant alternatives
  • Strong fit for clinical-stage and commercial pharma that already standardised on Vault Clinical, Vault Submissions, or Vault Safety
  • Public-company ownership (NYSE: VEEV) and a 17-year operating history give procurement teams the stability story their CFO wants
  • Native API and Vault Connections framework for clean data movement across Vault applications and external systems
Weaknesses
  • Pricing is opaque; SelectHub and Vendr triangulate $100K-$500K+/yr for mid-market and top-20-pharma deployments respectively
  • Multi-tenant SaaS with vendor-controlled validation timeline; customers cannot opt out of the three-release-per-year cadence even when they would prefer it
  • Best return on investment requires the customer to already run other Vault applications; standalone Vault QMS shoppers typically find better value elsewhere
  • Native CAPA and deviation depth is competitive with MasterControl and ETQ, but the EBR (electronic batch record) and shop-floor MES story is thinner than MasterControl Manufacturing Excellence or Sparta TrackWise Digital
  • Vendor lock-in is the strategic risk customers consistently raise; switching off Vault becomes harder with each adjacent application
  • Implementation typically requires Veeva certified partner involvement; partner costs commonly 25-40% of first-year licence for global pharma deployments
Best for

Pharma and biotech organisations already running two or more Veeva Vault applications (Clinical, RIM, Submissions, Safety) that want a QMS sharing the same validated data model and three-release-per-year cadence.

Worst for

Standalone QMS shoppers without an existing Vault footprint; the value proposition collapses without the Vault clinical / regulatory adjacencies, and the price tag remains enterprise-grade.

Key features

  • Deviation management with cross-site routing
  • CAPA workflow with effectiveness verification
  • Change control with multi-discipline approval
  • Complaints management aligned to MedWatch 3500A and EU PSUR
  • Supplier quality with audit and qualification tracking
  • Audit management for internal, supplier, and regulatory inspections
  • Quality issue management with risk-based escalation
  • Vault Connections for cross-application data movement

Integrations

40+ native. Notable: Veeva Vault Clinical Operations, Veeva Vault RIM, Veeva Vault Submissions, Veeva Vault Safety, SAP S/4HANA (via Vault Connections), Microsoft Entra ID, Native Vault API.

Target size

200 to 1,00,000 employees · US · Canada · EU · UK · AU · APAC · LATAM

#4

ETQ Reliance

ETQ (Hexagon AB subsidiary) · Founded 1992 · Burlington, MA, USA

Highly configurable enterprise EQMS with 40+ pre-built compliance applications across pharma and life sciences.

Opaque pricingG2 4.4 · Capterra 4.4 · 220+ reviews

Summary

ETQ was founded in 1992 and acquired by Hexagon AB in January 2022 for approximately $750M. ETQ Reliance is a configurable enterprise QMS that ships 40+ pre-built compliance applications spanning document control, training, CAPA, audit, supplier quality, change control, complaint handling, and risk register. Pharma customers use Reliance NXG for site-by-site validated rollouts plus the integration depth that Hexagon's manufacturing intelligence portfolio brings via Smart Manufacturing. ETQ is a Gartner Magic Quadrant QMS Leader (2024 placement); review patterns flag configurability as both the strongest selling point and the steepest implementation cost.

Strengths
  • Gartner Magic Quadrant QMS Leader (2024 placement); strong analyst credibility for regulated buyers running a parallel QMS bake-off
  • 40+ pre-built compliance applications including document control, training, CAPA, audit, supplier quality, change control, complaints, and risk register
  • Reliance NXG architecture supports site-by-site validated rollouts with delta-revalidation rather than full re-validation on platform updates
  • Hexagon ownership since January 2022 brings adjacent Manufacturing Intelligence, Asset Lifecycle Intelligence, and Smart Manufacturing portfolio depth
  • Configurable workflow and form designer means non-standard pharma processes (cell and gene therapy chain of identity, biologics deviation) can be modelled without code
  • Multi-site supplier quality with audit-history aggregation; well-suited to top-20 pharma with 30+ supplier sites
Weaknesses
  • Pricing is opaque and enterprise-tier; Vendr and SelectHub triangulate $80K-$300K+ entry for mid-market and $250K-$700K+ for top-20 pharma
  • Hexagon ownership is two-edged; the manufacturing-intelligence adjacency is real, but the corporate roadmap can re-prioritise the QMS line against bigger Hexagon bets
  • Configurability is a strength on day 365 and a tax on day 1; admin learning curve is steep and reviewers note time-to-first-validated-process
  • Implementation routinely 6-9 months with a Hexagon or partner systems integrator; total cost-to-go-live 25-40% of first-year licence
  • Smaller G2 / Capterra review base than MasterControl or Veeva Vault; harder to validate via peer-review patterns at the same sample size
  • Less natural fit for cloud-first emerging biotech; the configurability tax is unrecoverable at series-A scale
Best for

Large and global pharma running site-by-site validated rollouts who need a configurable enterprise QMS, deep supplier quality across many manufacturing sites, and an integration story with Hexagon Manufacturing Intelligence or Smart Manufacturing.

Worst for

Emerging biotech under series C and pre-commercial specialty pharma; the configurability tax and implementation effort do not survive the budget envelope.

Key features

  • Document control with 21 CFR Part 11 electronic signatures
  • Training management with role-based curricula
  • CAPA workflow with effectiveness verification
  • Change control with cross-functional routing
  • Supplier quality management with multi-site audit history
  • Audit management for internal, supplier, and regulatory
  • Complaint handling and adverse-event intake
  • Risk register with configurable scoring

Integrations

75+ native. Notable: SAP S/4HANA, Oracle E-Business Suite, Microsoft Entra ID, Salesforce, Hexagon Smart Manufacturing, Honeywell Forge, Native REST API.

Target size

500 to 1,00,000 employees · US · Canada · EU · UK · AU · APAC · LATAM

#5

Sparta TrackWise Digital

Sparta Systems (Honeywell company) · Founded 1994 · Hamilton, NJ, USA

Cloud-native QMS that succeeds the legacy TrackWise installed at 9 of the top 10 global pharma.

Opaque pricingG2 4.2 · Capterra 4.3 · 110+ reviews

Summary

Sparta Systems was founded in 1994 and built TrackWise into the historical pharma QMS incumbent; the legacy product is installed at 9 of the top 10 global pharmaceutical companies. Honeywell acquired Sparta in January 2021 for approximately $1.3B and folded the platform into Honeywell Forge. TrackWise Digital is the AWS-hosted cloud successor that ships native validation, configurable workflow, and AI-assisted deviation and CAPA triage; it is the migration target for legacy TrackWise customers and the new-deployment target for top-20 pharma running cloud-first quality strategies. Pricing is opaque and enterprise-tier; reference customers include large pharma, biotech, and medical-device manufacturers.

Strengths
  • Legacy TrackWise is installed at 9 of the top 10 global pharmaceutical companies per Sparta references; deepest top-pharma footprint of any QMS on this list
  • Cloud-native TrackWise Digital on AWS with native validation packages; cuts site-by-site validation effort 30-50% vs on-prem legacy TrackWise
  • Honeywell Forge adjacency since January 2021 brings Connected Plant, OT cybersecurity, and asset performance into the QMS conversation for top-20 pharma manufacturing
  • AI-assisted deviation and CAPA triage shipped in 2024-2025 releases; reviewers flag time-to-root-cause reductions of 30-40%
  • Strong fit for regulated customers already running Honeywell Experion DCS or Honeywell Forge OT platform across pharma manufacturing sites
  • Configurable workflow and form designer supports non-standard pharma processes (biologics, cell and gene therapy, sterile manufacturing)
Weaknesses
  • Pricing is opaque and enterprise-tier; SelectHub and Vendr triangulate $150K-$500K+/yr typical for mid-market pharma and $500K-$1.5M+/yr for top-20 deployments
  • Honeywell ownership since January 2021 brings corporate-roadmap risk; QMS prioritisation can shift against bigger Honeywell bets in OT and aerospace
  • Migration from legacy on-prem TrackWise to TrackWise Digital is non-trivial; reviewers note 6-12 months and 30-40% of new licence in services
  • Implementation requires Honeywell or certified partner involvement; the consultant bench is smaller than MasterControl or ETQ
  • Smaller G2 / Capterra review volume than MasterControl or Veeva Vault; review patterns trail the legacy-customer reference base
  • Less natural fit for emerging biotech and mid-market pharma; pricing and platform DNA are top-20-pharma-shaped
Best for

Top-20 global pharma, large biotech, and contract manufacturers running cloud-first quality strategies, especially those migrating from legacy on-prem TrackWise or already running Honeywell Forge / Experion across manufacturing sites.

Worst for

Emerging biotech under series C and small specialty pharma; the platform is priced and architected for top-20 pharma scale, not biotech budgets.

Key features

  • Deviation management with cross-site routing
  • CAPA workflow with AI-assisted root-cause triage
  • Change control with multi-discipline approval
  • Audit management for internal, supplier, and regulatory
  • Supplier quality with audit-history aggregation
  • Complaints management
  • Risk-based deviation triage with AI
  • Honeywell Forge adjacency for OT and Connected Plant

Integrations

50+ native. Notable: Honeywell Forge, Honeywell Experion DCS, SAP S/4HANA, Oracle E-Business Suite, Microsoft Entra ID, Veeva Vault (limited), Native REST API.

Target size

1,000 to 2,00,000 employees · US · Canada · EU · UK · AU · APAC · LATAM

#6

ComplianceQuest

ComplianceQuest, Inc. · Founded 2014 · Tampa, FL, USA

Salesforce-native EQMS plus EHS and PLM with 100% cloud architecture for regulated life sciences.

Opaque pricingG2 4.7 · Capterra 4.7 · 280+ reviews

Summary

ComplianceQuest was founded in 2014 and built a Salesforce-native EQMS for regulated industries with pharma, biotech, MedTech, and food and beverage as primary verticals. The product ships on the Salesforce platform with native validation packages and inherits Salesforce SSO, mobile, AppExchange, and Einstein AI. Coverage spans document control, training, CAPA, audit, supplier quality, change control, complaint handling, EHS, and PLM in one tenant. Insight Partners took a minority position in 2022. ComplianceQuest is a Gartner Magic Quadrant QMS Visionary; review patterns flag the Salesforce DNA as the deciding factor for buyers already running Salesforce Sales Cloud or Service Cloud.

Strengths
  • Salesforce-native architecture means inherited Salesforce SSO, mobile, AppExchange, and Einstein AI features without separate integration work
  • 100% cloud-native with multi-tenant SaaS and validated configuration; faster time-to-validated-go-live than on-prem QMS competitors
  • Coverage spans EQMS + EHS + PLM in one tenant, useful for combined pharma quality + manufacturing-safety + product-development briefs
  • Gartner Magic Quadrant QMS Visionary placement; strong analyst credibility for parallel bake-offs against MasterControl and ETQ
  • Independent ownership with Insight Partners minority investment 2022; no full-PE renewal-pressure dynamic
  • Strong fit for pharma customers already running Salesforce Sales Cloud, Service Cloud, or Marketing Cloud who want to consolidate quality on the same data platform
Weaknesses
  • Pricing is opaque; Vendr and SelectHub triangulate $60K-$200K+/yr typical for mid-market pharma; per-user Salesforce licensing layers on top
  • Salesforce dependency is two-edged; non-Salesforce pharma absorbs a platform tax, and a future Salesforce price-uplift cascades to ComplianceQuest customers
  • Legacy on-prem TrackWise customers and Veeva Vault customers find migration friction higher than ComplianceQuest marketing suggests; the data-model translation is real
  • Smaller G2 / Capterra review base than MasterControl, Veeva Vault, or ETQ; harder to validate via peer-review patterns
  • Native CAPA and deviation depth is competitive at mid-market scale but trails MasterControl and ETQ at top-20-pharma site-by-site validated rollout scale
  • Implementation typically requires ComplianceQuest or certified partner involvement; the consultant bench is smaller than MasterControl or Veeva
Best for

Mid-market and growing pharma, biotech, and MedTech customers already running Salesforce Sales Cloud, Service Cloud, or Marketing Cloud who want a cloud-native EQMS that shares the same data platform.

Worst for

Pharma running on SAP S/4HANA or Oracle E-Business Suite without a Salesforce footprint; the Salesforce platform tax does not amortise without an existing Salesforce contract.

Key features

  • Document control with 21 CFR Part 11 electronic signatures
  • Training management with Salesforce mobile
  • CAPA workflow with Einstein AI root-cause assistance
  • Change control with Salesforce approval routing
  • Supplier quality management with AppExchange ecosystem
  • Audit management for internal, supplier, and regulatory
  • EHS module for manufacturing safety
  • PLM module for product lifecycle

Integrations

100+ native. Notable: Salesforce AppExchange ecosystem, Microsoft Entra ID, SAP S/4HANA (via Salesforce Connect), Microsoft 365, Slack, Tableau, Native Salesforce API.

Target size

100 to 25,000 employees · US · Canada · EU · UK · AU · APAC

#7

Greenlight Guru

Greenlight Guru, Inc. · Founded 2013 · Indianapolis, IN, USA

MedTech-first eQMS for combination products and pharma with a primary medical-device DNA.

Partial pricingG2 4.6 · Capterra 4.7 · 1050+ reviews

Summary

Greenlight Guru was founded in 2013 in Indianapolis and built the MedTech-first eQMS category around 21 CFR Part 820 design controls and ISO 13485. The platform supports CAPA, complaint handling, audit, supplier quality, change control, and risk management with native templates for FDA 510(k), De Novo, PMA, and EU MDR / IVDR technical files. JMI Equity led a growth investment in 2021. The pharma fit is in combination products (drug-device combinations under 21 CFR Part 4) and at biotechs whose pipeline includes device-delivered therapeutics. Greenlight Guru is a G2 Leader across MedTech QMS categories; review patterns highlight ease-of-use as the deciding factor for emerging combination-product organisations.

Strengths
  • Purpose-built for 21 CFR Part 820 design controls and ISO 13485; strongest fit for combination products (21 CFR Part 4) and drug-device combinations
  • Native templates for FDA 510(k), De Novo, PMA, and EU MDR / IVDR technical files
  • G2 Leader across MedTech eQMS categories with 1,000+ reviews and consistent 4.5+ ease-of-use scores
  • Strong fit for emerging combination-product organisations needing one platform for device design + drug GxP
  • JMI Equity ownership since 2021; growth-stage PE rather than mature-PE renewal-pressure dynamic (yet)
  • Modern cloud UI that reviewers consistently flag as the deciding factor against legacy on-prem QMS competitors
Weaknesses
  • Primary DNA is MedTech; pure-pharma manufacturers without a device component find native 21 CFR Part 211 GMP and ICH Q10 depth thinner than MasterControl or ETQ
  • Pricing is partially opaque; entry tier published around $25K-$40K/yr but enterprise pricing routes through a quote workflow
  • Less natural fit for top-20 pharma with 30+ manufacturing sites; the architecture is shaped for mid-market combination-product and MedTech buyers
  • Native batch-record (EBR) and shop-floor MES story is absent; pharma manufacturing customers need to layer a separate MES
  • JMI Equity growth investment 2021 will eventually convert to renewal-pricing pressure typical of PE-owned cycles
  • Implementation typically 3-6 months for combination products; faster than enterprise QMS competitors but still requires partner involvement for validated rollouts
Best for

Combination-product organisations (21 CFR Part 4 drug-device), MedTech with biologics pipelines, and biotechs whose pipeline includes device-delivered therapeutics who want one eQMS for design controls plus drug GxP.

Worst for

Pure-pharma manufacturers without a device component; native 21 CFR Part 211 GMP and ICH Q10 depth trails MasterControl, ETQ, and TrackWise Digital.

Key features

  • Design controls (21 CFR Part 820.30 and ISO 13485 §7.3)
  • Document control with 21 CFR Part 11 electronic signatures
  • CAPA workflow with effectiveness verification
  • Complaint handling aligned to MedWatch 3500A
  • Audit management for internal, supplier, and FDA
  • Supplier quality management
  • Risk management (ISO 14971)
  • Combination-product workflow (21 CFR Part 4)

Integrations

30+ native. Notable: Microsoft Entra ID, Okta, Jira, Salesforce, Microsoft 365, Slack, Native REST API.

Target size

10 to 2,500 employees · US · Canada · EU · UK · AU

#8

Qualio

Qualio, Inc. · Founded 2012 · San Francisco, CA, USA

Cloud-native EQMS published at $24K-$50K entry for emerging biotech, generics, and CDMO clients.

Partial pricingG2 4.6 · Capterra 4.7 · 380+ reviews

Summary

Qualio was founded in 2012 in Dublin and now headquartered in San Francisco; the platform targets emerging biotech, generics, virtual pharma, and contract development and manufacturing organisations (CDMOs) under 250 staff. Pricing is the most transparent in this ranking after Greenlight Guru, with Essentials at approximately $24K/yr and Plus around $50K/yr. Coverage spans document control, training, CAPA, audit, supplier quality, change control, and risk register in a cloud-native multi-tenant SaaS shape. Qualio is a G2 Leader for QMS at small-business and mid-market scale; review patterns highlight 60-90-day time-to-validated-deployment as the deciding factor for emerging biotechs racing toward Phase 1 IND.

Strengths
  • Published $24K-$50K entry pricing; the most transparent in this ranking outside Greenlight Guru
  • Cloud-native multi-tenant SaaS with 60-90-day time-to-validated-deployment; fastest first-Phase-1-readiness in the ranking
  • Targeted at emerging biotech, generics, virtual pharma, and CDMOs under 250 staff; product DNA matches the buyer profile
  • G2 Leader for QMS at small-business and mid-market scale with 350+ reviews and 4.5+ ease-of-use scores
  • Native 21 CFR Part 11 electronic signatures and ISO 13485 readiness in the Essentials tier; no upcharge for the core regulated workflow
  • Independent ownership with Sapphire Ventures + Series B Capital led Series B in 2021; growth-stage VC rather than mature-PE renewal-pressure dynamic
Weaknesses
  • Targeted at sub-250-staff customers; commercial-stage pharma manufacturers and top-20 pharma typically outgrow the platform within 18-24 months
  • Native CAPA and deviation depth is competitive at biotech scale but trails MasterControl, ETQ, and Veeva Vault at site-by-site validated rollout
  • No native EBR (electronic batch record) or shop-floor MES; commercial-stage manufacturing customers need to layer a separate system
  • Smaller integration count than ComplianceQuest or Veeva Vault; pharma customers running SAP S/4HANA or Oracle ERP face heavier integration lift
  • Less natural fit for combination products with deep 21 CFR Part 820 design controls; Greenlight Guru is the better pick when device dominates
  • Multi-tenant SaaS with vendor-controlled release cadence; pharma legal teams that require single-tenant deployment for validated environments need to look at RiskWatch or MasterControl
Best for

Emerging biotech, virtual pharma, generics, specialty pharma, and CDMOs under 250 staff that need a validated cloud EQMS stood up in 60-90 days for under $50K to support a first IND or Phase 1 trial.

Worst for

Top-20 global pharma with 30+ manufacturing sites or commercial-stage manufacturers with EBR / MES needs; the platform is shaped for the emerging end of the market.

Key features

  • Document control with 21 CFR Part 11 electronic signatures
  • Training management with read-and-understand tracking
  • CAPA workflow with root-cause analysis
  • Change control with cross-functional routing
  • Audit management for internal and supplier
  • Supplier quality management
  • Risk register
  • Cloud-native mobile experience

Integrations

20+ native. Notable: Microsoft Entra ID, Okta, Microsoft 365, Google Workspace, Slack, Salesforce, Native REST API.

Target size

10 to 250 employees · US · Canada · EU · UK · AU

#9

Pilgrim Quality Solutions

IQVIA (Pilgrim is an IQVIA company) · Founded 1995 · Tampa, FL, USA

IQVIA-aligned validated QMS with SmartSolve EQMS and iComplyGRC for compliance and supplier risk.

Opaque pricingG2 4.2 · Capterra 4.4 · 130+ reviews

Summary

Pilgrim Quality Solutions was founded in 1995 and acquired by IQVIA in 2015. The SmartSolve EQMS suite covers document control, training, CAPA, change control, audit, supplier quality, and complaint handling with native templates for pharmaceutical, MedTech, and life-sciences customers. The iComplyGRC adjacency supports compliance and supplier risk for pharma customers running clinical-stage and commercial programmes alongside IQVIA's broader clinical and commercial services. Pilgrim serves 800+ customers across pharma, biotech, MedTech, and life sciences. The IQVIA ownership is the deciding factor for pharma customers who already run IQVIA clinical, commercial, or technology services.

Strengths
  • IQVIA ownership since 2015; natural alignment with IQVIA clinical, commercial, and technology services used across mid-market and top-20 pharma
  • 800+ regulated-life-sciences customers across pharma, biotech, MedTech, and clinical research
  • SmartSolve EQMS covers full GxP envelope (documents, training, CAPA, change control, audit, supplier quality, complaints)
  • iComplyGRC adjacency adds compliance and supplier risk in the same data fabric for buyers running combined briefs
  • 30-year operating history with regulated life-sciences customers; consistent ISPE and PDA conference presence
  • Validated environment with native 21 CFR Part 11 electronic signatures and Annex 11 alignment
Weaknesses
  • Pricing is opaque; Vendr and SelectHub triangulate $50K-$200K+/yr typical for mid-market pharma
  • Brand recognition outside IQVIA-aligned customers is lower than MasterControl, Veeva Vault, or ETQ; review volume on G2 / Capterra trails the leaders
  • Modern cloud UI trails ComplianceQuest, Qualio, and Greenlight Guru; reviewers flag UI generations behind cloud-first competitors
  • IQVIA ownership is two-edged; the clinical and commercial adjacency is real, but IQVIA's strategic priorities can shift QMS investment cycles
  • Implementation typically 4-8 months with Pilgrim or IQVIA partner involvement; total cost-to-go-live 20-30% of first-year licence
  • Native EBR (electronic batch record) and shop-floor MES story is thinner than MasterControl Manufacturing Excellence or TrackWise Digital
Best for

Mid-market pharma, biotech, and MedTech customers already running IQVIA clinical, commercial, or technology services who want a validated EQMS sharing the IQVIA data fabric.

Worst for

Pharma not aligned to IQVIA who would otherwise pick a cloud-first competitor on UI and integration; the value proposition collapses without an existing IQVIA footprint.

Key features

  • SmartSolve document control with 21 CFR Part 11 electronic signatures
  • Training management with role-based curricula
  • CAPA workflow with root-cause analysis
  • Change control with cross-functional routing
  • Audit management for internal, supplier, and regulatory
  • Supplier quality management
  • Complaint handling and adverse-event intake
  • iComplyGRC compliance and supplier risk adjacency

Integrations

35+ native. Notable: IQVIA clinical and commercial platforms, SAP S/4HANA, Oracle E-Business Suite, Microsoft Entra ID, Salesforce, Microsoft 365, Native REST API.

Target size

100 to 25,000 employees · US · Canada · EU · UK · AU · APAC · LATAM

#10

Optro (formerly AuditBoard)

Optro, Inc. · Founded 2014 · Cerritos, CA, USA

Internal-audit-first GRC suite that owns SOX 404, IT general controls, and CSA-aligned IT risk alongside a pharma QMS.

Opaque pricingG2 4.6 · Capterra 4.7 · 1820+ reviews

Summary

Optro is the new name for AuditBoard, announced March 9 2026. Founded in 2014 as SOXHUB, rebranded to AuditBoard in 2017, and acquired by Hg Capital in May 2024 for over $3 billion. The platform supports SOX 404, ITGC testing, ISO 27001, SOC 2, NIST CSF, and connected-risk dashboards. G2 carries 1,585+ reviews at 4.6/5 as of May 2026. Pharma fit is in public-company life-sciences organisations where internal audit owns SOX 404 + IT general controls + Computer Software Assurance (CSA) testing of validated systems alongside (not instead of) a QMS like MasterControl, Veeva Vault, or ETQ. Buyers shopping for a single tool to own GMP CAPA, deviation, and batch records will find Optro the wrong fit; buyers shopping for SOX + ITGC + CSA on top of an existing QMS will find it the right one.

Strengths
  • 1,585+ G2 reviews at 4.6/5 (May 2026), the highest review volume across all GRC platforms
  • Deepest internal-audit and SOX 404 workflow in the category; public-company pharma internal-audit teams find it intuitive
  • ITGC and Computer Software Assurance (CSA) testing fit for the post-September 2022 FDA risk-based testing approach for validated systems
  • CrossComply mapping engine auto-detects shared controls across SOX, ISO 27001, SOC 2, and NIST CSF for combined briefs
  • Optro AI features support evidence summarisation and control-narrative drafting (post-rebrand product investment)
  • Fortune 500 life-sciences reference customers and Big Four advisory firm partnerships
Weaknesses
  • Not a validated EQMS; does not own GMP CAPA, deviation, change control, batch records, or training in the MasterControl / Veeva Vault sense
  • Hg Capital ownership since May 2024 raises typical PE-owned price-uplift risk (8-15% at renewal)
  • Brand-rebrand churn (March 2026 AuditBoard to Optro) means a year of customer-comms work that distracts product velocity
  • Pricing remains opaque; SmartSuite and SelectHub triangulate $30K-$80K+ entry; $60K-$150K typical for pharma buyers with multi-framework briefs
  • No native 21 CFR Part 11 framework library for QMS use cases; the platform addresses IT-side compliance, not GxP-side
  • Implementation is consultant-heavy; expect 8-16 weeks with a named systems integrator for pharma deployments
Best for

Public-company pharma, large biotech, and contract manufacturers where internal audit owns SOX 404, IT general controls, and CSA-aligned IT risk testing of validated systems alongside (not instead of) a QMS.

Worst for

Quality-led pharma buyers shopping for a single tool to own GMP CAPA, deviation, change control, training, and batch records; the platform DNA is internal-audit, not pharmaceutical quality.

Key features

  • Internal audit planning, fieldwork, and reporting
  • SOX 404 controls testing and ICFR workflow
  • ITGC and Computer Software Assurance (CSA) testing
  • ISO 27001, SOC 2, NIST CSF framework support
  • CrossComply control-mapping across frameworks
  • Third-party risk management with vendor scoring
  • Optro AI for evidence summarisation
  • Connected-risk dashboards for board reporting

Integrations

60+ native. Notable: Workday, NetSuite, SAP, Microsoft Entra ID, Okta, Jira, ServiceNow.

Target size

500 to 1,00,000 employees · US · Canada · UK · EU · AU

Step by step

Buying guide

Walk these steps in order. The shortlist falls out of step 1, the negotiation moves come together in step 6, and step 8 closes the deal.

  1. 1

    Name the primary buyer profile in one sentence

    Pharma compliance shortlists fall out of four buyer profiles. Profile A: a commercial-stage manufacturer running 21 CFR Part 11 + ICH Q10 + GMP at 1 to 30+ sites with a single validated EQMS. Profile B: a clinical-stage or pre-commercial biotech running its first IND or Phase 1 trial. Profile C: a combination-product MedTech running 21 CFR Part 820 design controls alongside 21 CFR Part 211 GMP. Profile D: a public-company pharma where internal audit owns SOX 404 + IT general controls + CSA-aligned validated-systems testing alongside a quality-led EQMS. Write down which profile you fit before reading product cards; the ranking changes by profile.

  2. 2

    Map your frameworks before you shortlist tools

    Write down every regulatory framework you must demonstrate compliance against in the next 24 months. Typical commercial-stage manufacturer stack: 21 CFR Part 11, 21 CFR Part 210 / 211, ICH Q10, ICH Q9, ISPE GAMP 5, EMA Annex 11 + Annex 15, MHRA Data Integrity ALCOA+, DSCSA. Typical combination-product stack: the above plus 21 CFR Part 820 design controls, ISO 13485, ISO 14971, EU MDR or IVDR. Typical public-company pharma stack: the above plus SOX 404, ITGC, SOC 2, ISO 27001, NIST CSF. Platforms with library depth for your specific stack win; platforms that hand-map are taxed.

  3. 3

    Filter by employee count and budget band first

    Under 50 staff with a sub-$50K budget filters in only Qualio Essentials and the lower Greenlight Guru tier. 50 to 250 staff with $50K-$100K opens Qualio Plus, Greenlight Guru Growth, ComplianceQuest mid-market, and Pilgrim. 250 to 2,500 staff with $100K-$300K opens MasterControl, ETQ Reliance, Veeva Vault QMS clinical-stage, RiskWatch Professional / Enterprise, and Optro. 2,500+ staff with $300K+ opens all ten with Sparta TrackWise Digital, Veeva Vault QMS commercial, MasterControl Global, and ETQ Reliance Global doing most of the work.

  4. 4

    Validate 21 CFR Part 11 coverage at the sub-section level

    Every vendor will tell you they cover 21 CFR Part 11. Ask each one to show you their pre-built control library mapped to § 11.10 (controls for closed systems), § 11.30 (controls for open systems), § 11.50 (signature manifestation), § 11.70 (signature-record linking), § 11.100 (unique identification), § 11.200 (electronic signature components), and § 11.300 (password controls). Ask which sub-sections are pre-mapped versus which require manual configuration. Ask whether the vendor will share their most-recent 21 CFR Part 11 self-assessment and any FDA Form 483 inspection observations involving the platform. A 30-minute exercise here cuts a 6-month implementation surprise.

  5. 5

    Pressure-test the ISPE GAMP 5 category fit

    ISPE GAMP 5 second edition (July 2022) defines software categories (Category 3 non-configured commercial products, Category 4 configured commercial products, Category 5 custom-built). Validated EQMS like MasterControl, Veeva Vault QMS, ETQ Reliance, and TrackWise Digital ship as Category 4 configured products. Ask each vendor to publish their GAMP 5 category, their reference validation package, and their position on Computer Software Assurance (CSA) for the post-September 2022 risk-based testing approach. Cloud-native multi-tenant SaaS vendors handle more infrastructure validation than on-prem competitors; price the difference into your TCO model.

  6. 6

    Pull the G2 and Capterra review patterns from the last 12 months

    Read 20+ verified reviews per shortlisted vendor from the last 12 months. Look for patterns, not single outliers. Patterns we observe in pharma specifically: 'FDA reference customer earns trust on day one' (MasterControl); 'value collapses without other Vault apps' (Veeva Vault QMS); 'configurability is a tax on day 1 and a moat on day 365' (ETQ Reliance); 'fastest validated-deployment we have seen' (Qualio); 'Salesforce DNA is the deciding factor' (ComplianceQuest); 'overkill for our size' (Sparta TrackWise Digital at sub-1,000 staff). Confirm or rebut the patterns with reference calls.

  7. 7

    Insist on a 30-day pilot with your real validated data, not a demo

    Demos are choreographed; pilots are not. Ask each finalist for a 30-day pilot with: three control framework imports (21 CFR Part 11 + ICH Q10 + GAMP 5), one supplier qualification record, one CAPA workflow exercise, one change-control approval routing test, and one inspector-ready export. The platform that handles your real validated data without three weeks of professional services is the one that will survive an FDA Form 483 or EMA inspection. If a vendor refuses a working pilot, escalate or walk.

  8. 8

    Ask for the renewal-escalator cap and the data-residency clause in writing

    Renewal-pricing pressure is the silent budget killer in pharma compliance. PE-owned vendors (MasterControl / Sumeru, ETQ / Hexagon, Sparta / Honeywell, Optro / Hg Capital) routinely push 8-15% uplifts. Ask for the renewal-escalator cap in the master agreement and walk if the vendor refuses. Separately, ask where your validated GxP records live, who can access them, and what happens if you terminate. RiskWatch and MasterControl both support single-tenant deployment with customer-owned data residency; Veeva Vault QMS, ComplianceQuest, Qualio, and TrackWise Digital are multi-tenant SaaS where the BAA-equivalent quality agreement is the data-residency control.

  9. 9

    Run the decision matrix on this page with your own weights

    The default methodology weights on this page (20% Ease, 20% Features, 20% Value, 15% Support, 15% Scalability, 10% Integrations) reflect a generic mid-market pharma buyer. Top-20 pharma should push Scalability and Integrations up; emerging biotech should push Ease of Use and Value up; combination-product MedTech should push Features up (design controls plus GMP); public-company pharma running internal-audit-led briefs should push Integrations up and consider Optro as a parallel tool to a primary EQMS. Use the decision-matrix slider on this page to re-rank with your weights before booking demos.

Frequently asked

Buyer questions, answered

The eight questions our pre-sales team hears the most often when buyers compare this category.

What is pharmaceutical compliance management software?
Pharmaceutical compliance management software is a category of platforms that help drug manufacturers, biotech, contract development and manufacturing organisations, and combination-product companies manage 21 CFR Part 11 electronic records and signatures, the GxP envelope (GMP, GLP, GCP, GDP, GVP), ICH Q10 pharmaceutical quality system, ISPE GAMP 5 validated systems, EMA Annex 11 and Annex 15, MHRA Data Integrity, DSCSA trading-partner readiness, and FDA Computer Software Assurance (CSA) for risk-based testing. The ten platforms in this ranking each solve part of that brief; none solves all of it equally well, which is why the right pick depends on whether the buyer is a commercial-stage manufacturer, a clinical-stage biotech, a combination-product MedTech, or a public-company pharma with an internal-audit-led IT compliance brief.
Which platform is the best fit for an emerging biotech preparing for a first IND or Phase 1 trial?
Qualio is the closest fit for emerging biotechs under series C and virtual pharma preparing for a first IND or Phase 1 trial. The Essentials tier is published around $24K/yr, the Plus tier around $50K/yr, and time-to-validated-deployment is 60-90 days. Greenlight Guru is the strongest pick when the pipeline includes a device-delivered therapeutic or combination product because the 21 CFR Part 820 design-controls depth is the deciding factor. Larger biotech and commercial-stage manufacturers typically outgrow Qualio within 18-24 months and migrate to MasterControl, Veeva Vault QMS, or ETQ Reliance.
Which platform handles 21 CFR Part 11 plus GAMP 5 plus DSCSA in one tenant?
RiskWatch ships 21 CFR Part 11, ISPE GAMP 5 second-edition (July 2022) categories, ICH Q10, EMA Annex 11 + Annex 15, MHRA Data Integrity, DSCSA, and 35+ other frameworks in one tenant with cross-mapping between common controls. MasterControl and Veeva Vault QMS both carry deep 21 CFR Part 11 and GAMP 5 fit out of the box but treat DSCSA trading-partner attestation as an adjacent workstream rather than a first-class library. For pharma running 3+ frameworks (21 CFR Part 11 + GAMP 5 + ICH Q10 + Annex 11 + DSCSA) the consolidation logic favours RiskWatch; for pharma running a single validated EQMS the case for MasterControl or Veeva Vault is competitive.
How much should a pharma manufacturer budget for compliance management software in 2026?
Entry pricing ranges from approximately $24K/yr (Qualio Essentials) to $1.5M+/yr (Sparta TrackWise Digital top-20-pharma deployments). An emerging biotech preparing for Phase 1 typically spends $25K-$60K/yr on licence plus 10-20% in implementation services. A mid-market commercial-stage pharma spending across QMS + supplier quality + audit routinely spends $80K-$250K/yr on a single platform plus 20-30% in implementation. A top-20 global pharma running site-by-site validated rollouts across 30+ manufacturing sites routinely spends $500K-$2M/yr across multiple modules from one or two vendors. Always model 3-year total cost of ownership and ask for the renewal-escalator cap in writing.
How does FDA Computer Software Assurance (CSA) change the buying brief?
FDA published the draft Computer Software Assurance (CSA) guidance in September 2022, shifting the validated-systems testing approach from prescriptive Computer System Validation (CSV) to risk-based assurance. The practical consequence is that pharma QA and IT teams can spend less effort on low-risk script-driven testing and more on unscripted exploratory testing for high-risk functions. The platforms that adapt fastest to CSA are the cloud-native ones (Veeva Vault QMS, ComplianceQuest, Qualio, TrackWise Digital) because the vendor handles infrastructure validation and the customer focuses on configuration and use-case risk. Legacy on-prem CSV-shaped vendors (older MasterControl on-prem, legacy TrackWise) require more customer-side effort to align validation packages with CSA. Ask each vendor to show their published CSA approach in writing before signing.
Which platforms handle DSCSA trading-partner readiness after the November 2024 stabilization period and the May 2025 exemptions year?
DSCSA trading-partner readiness is not a native first-class workflow in most pharma compliance platforms; it sits in the broader serialization and supply-chain category (TraceLink, rfxcel, Movilitas, SAP ATTP). The ten platforms in this ranking handle DSCSA at the compliance and supplier-attestation layer rather than at the EPCIS serialization layer. RiskWatch ships a DSCSA framework library as part of the 40+ pre-mapped controls; MasterControl, Veeva Vault QMS, ETQ Reliance, and TrackWise Digital handle DSCSA through supplier quality and trading-partner attestation workflows. The FDA's Stabilization Period extension to November 27 2024 and the Exemptions Year extension to May 27 2025 give late adopters runway, but trading-partner attestation is a hard requirement now. Pair one of these platforms with a serialization specialist for the full DSCSA stack.
Are any of these platforms validated as 21 CFR Part 11 compliant out of the box?
21 CFR Part 11 compliance is a customer responsibility, not a vendor claim. The FDA does not certify software as 21 CFR Part 11 compliant; vendors ship features (audit trail, electronic signatures, access controls, time-stamped records) that customers configure and validate to meet 21 CFR Part 11 obligations. MasterControl, Veeva Vault QMS, ETQ Reliance, Sparta TrackWise Digital, ComplianceQuest, Greenlight Guru, Qualio, and Pilgrim all ship the technical features (§ 11.10 electronic record controls, § 11.50 signature manifestation, § 11.70 signature-record linking, § 11.100 unique identification, § 11.300 password controls). RiskWatch supports 21 CFR Part 11 as a framework library mapping rather than as a native validated EQMS. Always request the vendor's most-recent 21 CFR Part 11 self-assessment, validation package summary, and any FDA Form 483 inspection observations involving the platform before signing.
Does RiskWatch accept any money from the other vendors on this page?
No. RiskWatch accepts no affiliate fees, sponsorship money, or paid placements on this page. RiskWatch is also on the page, at #1. Readers should weigh the publishing relationship against the published evidence on this page.
Definitions

Glossary

Definitions for the acronyms and jargon used on this page. Useful for sharing with non-specialist stakeholders on the buying committee.

21 CFR Part 11
US Food and Drug Administration regulation (Title 21, Code of Federal Regulations, Part 11) governing electronic records and electronic signatures in regulated pharma, biotech, and MedTech. Covers controls for closed systems (§ 11.10), signature manifestation (§ 11.50), signature-record linking (§ 11.70), unique identification (§ 11.100), and password controls (§ 11.300). Every validated EQMS in this ranking ships features customers configure to meet 21 CFR Part 11 obligations.
GxP
Collective term for the good-practice regulations governing pharmaceutical and life-sciences operations: Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Good Distribution Practice (GDP), and Good Pharmacovigilance Practice (GVP). The GxP envelope is the regulatory perimeter for pharma compliance management software; coverage depth varies by vendor and lifecycle stage.
ICH Q10
International Council for Harmonisation Quality Guideline Q10: Pharmaceutical Quality System (PQS). Defines the framework for a modern pharmaceutical quality management system across the product lifecycle from development through commercial manufacturing to product discontinuation. Most validated EQMS platforms in this ranking ship ICH Q10 as the underlying quality-system reference architecture.
ISPE GAMP 5
ISPE Good Automated Manufacturing Practice version 5 (second edition published July 2022). The pharma industry's reference framework for validated computerized systems. Defines software categories (Category 3 non-configured commercial products, Category 4 configured commercial products, Category 5 custom-built) and the corresponding validation approach. RiskWatch, MasterControl, Veeva Vault QMS, and Sparta TrackWise Digital all ship GAMP 5 mapping.
EMA Annex 11
European Medicines Agency Annex 11 to the EU GMP Guide, covering computerised systems in regulated pharma and biotech operations. The European counterpart to FDA 21 CFR Part 11 with similar but not identical requirements for risk management, validation, audit trail, electronic signatures, and data integrity. Annex 15 covers qualification and validation more broadly.
DSCSA
US Drug Supply Chain Security Act (2013). Mandates electronic, interoperable, package-level traceability across the pharmaceutical supply chain. The FDA's Stabilization Period was extended to November 27 2024 and the Exemptions Year was extended to May 27 2025 to give trading partners runway, but trading-partner attestation is now a hard requirement. Most platforms in this ranking address DSCSA at the supplier-attestation layer; full EPCIS serialization sits in adjacent vendors like TraceLink and rfxcel.
Computer Software Assurance (CSA)
FDA draft guidance published September 2022 introducing a risk-based testing approach for validated software in regulated environments. Replaces the prescriptive Computer System Validation (CSV) approach with a focus on critical-thinking risk assessment and unscripted exploratory testing for high-risk functions. Cloud-native EQMS platforms benefit most from CSA because the vendor handles infrastructure validation while the customer focuses on configuration and use-case risk.
Final word

So which one should a pharma buyer pick?

If you read this page top to bottom and one platform stood out for your buyer profile (commercial-stage manufacturer, emerging biotech, combination-product MedTech, or public-company pharma with an internal-audit-led IT brief), that is your answer. The methodology is on this page so a pharma QA director, a clinical-stage CTO, or a combination- product regulatory lead can disagree with the rank and arrive at a different first pick honestly. The position reflects our weights and the public evidence as of 2026-05-15.

Whatever you shortlist, insist on three contract terms before you sign: a 30-day working pilot with your real validated records (not a choreographed demo), a renewal-escalator cap written into the master subscription agreement, and a documented exit clause covering data-export format, retention, and price. The pharma buyers we see lose three-year deals lose them on those three terms, not on feature coverage.

If you would like the RiskWatch demo specifically tuned to 21 CFR Part 11, GAMP 5, ICH Q10, Annex 11, and DSCSA in one tenant, request it at riskwatch.com/request-a-demo. If you would like a no-strings second-opinion on one of the other nine, email sales@riskwatch.com with the vendor name in the subject line and we will share what we know.

Request a Demo